vs

Side-by-side financial comparison of ICHOR HOLDINGS, LTD. (ICHR) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.

ICHOR HOLDINGS, LTD. is the larger business by last-quarter revenue ($223.6M vs $207.8M, roughly 1.1× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -7.1%, a 64.5% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $5.9M).

Ichor Holdings Ltd. designs, manufactures and supplies critical fluid delivery systems, subsystems and related components for the global semiconductor manufacturing sector. Its products are integrated into front-end wafer processing equipment, supporting production of advanced logic, memory and specialty chips for leading semiconductor device and equipment makers across North America, East Asia and Europe.

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.

ICHR vs IDYA — Head-to-Head

Bigger by revenue
ICHR
ICHR
1.1× larger
ICHR
$223.6M
$207.8M
IDYA
Higher net margin
IDYA
IDYA
64.5% more per $
IDYA
57.4%
-7.1%
ICHR
More free cash flow
IDYA
IDYA
$136.3M more FCF
IDYA
$142.2M
$5.9M
ICHR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ICHR
ICHR
IDYA
IDYA
Revenue
$223.6M
$207.8M
Net Profit
$-16.0M
$119.2M
Gross Margin
9.4%
Operating Margin
-6.2%
52.2%
Net Margin
-7.1%
57.4%
Revenue YoY
-4.2%
Net Profit YoY
-304.8%
330.1%
EPS (diluted)
$-0.46
$1.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICHR
ICHR
IDYA
IDYA
Q4 25
$223.6M
Q3 25
$239.3M
$207.8M
Q2 25
$240.3M
Q1 25
$244.5M
Q4 24
$233.3M
Q3 24
$211.1M
$0
Q2 24
$203.2M
$0
Q1 24
$201.4M
$0
Net Profit
ICHR
ICHR
IDYA
IDYA
Q4 25
$-16.0M
Q3 25
$-22.9M
$119.2M
Q2 25
$-9.4M
Q1 25
$-4.6M
Q4 24
$-3.9M
Q3 24
$-2.8M
$-51.8M
Q2 24
$-5.1M
$-52.8M
Q1 24
$-9.0M
$-39.6M
Gross Margin
ICHR
ICHR
IDYA
IDYA
Q4 25
9.4%
Q3 25
4.6%
Q2 25
11.3%
Q1 25
11.7%
Q4 24
11.6%
Q3 24
13.2%
Q2 24
12.6%
Q1 24
11.4%
Operating Margin
ICHR
ICHR
IDYA
IDYA
Q4 25
-6.2%
Q3 25
-8.1%
52.2%
Q2 25
-2.0%
Q1 25
-0.5%
Q4 24
-0.5%
Q3 24
-0.2%
Q2 24
-1.1%
Q1 24
-1.9%
Net Margin
ICHR
ICHR
IDYA
IDYA
Q4 25
-7.1%
Q3 25
-9.6%
57.4%
Q2 25
-3.9%
Q1 25
-1.9%
Q4 24
-1.7%
Q3 24
-1.3%
Q2 24
-2.5%
Q1 24
-4.5%
EPS (diluted)
ICHR
ICHR
IDYA
IDYA
Q4 25
$-0.46
Q3 25
$-0.67
$1.33
Q2 25
$-0.28
Q1 25
$-0.13
Q4 24
$-0.11
Q3 24
$-0.08
$-0.60
Q2 24
$-0.15
$-0.68
Q1 24
$-0.30
$-0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICHR
ICHR
IDYA
IDYA
Cash + ST InvestmentsLiquidity on hand
$98.3M
$786.9M
Total DebtLower is stronger
$123.5M
Stockholders' EquityBook value
$663.9M
$1.1B
Total Assets
$942.9M
$1.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICHR
ICHR
IDYA
IDYA
Q4 25
$98.3M
Q3 25
$92.5M
$786.9M
Q2 25
$92.2M
Q1 25
$109.3M
Q4 24
$108.7M
Q3 24
$116.4M
$920.0M
Q2 24
$114.3M
$701.7M
Q1 24
$102.1M
$698.8M
Total Debt
ICHR
ICHR
IDYA
IDYA
Q4 25
$123.5M
Q3 25
$123.5M
Q2 25
$125.0M
Q1 25
$126.8M
Q4 24
$128.5M
Q3 24
$130.3M
Q2 24
$130.2M
Q1 24
$131.9M
Stockholders' Equity
ICHR
ICHR
IDYA
IDYA
Q4 25
$663.9M
Q3 25
$676.2M
$1.1B
Q2 25
$694.1M
Q1 25
$700.4M
Q4 24
$698.3M
Q3 24
$697.3M
$1.2B
Q2 24
$694.9M
$931.7M
Q1 24
$697.2M
$935.3M
Total Assets
ICHR
ICHR
IDYA
IDYA
Q4 25
$942.9M
Q3 25
$966.6M
$1.2B
Q2 25
$985.1M
Q1 25
$1.0B
Q4 24
$995.6M
Q3 24
$975.9M
$1.2B
Q2 24
$947.7M
$973.7M
Q1 24
$957.4M
$961.5M
Debt / Equity
ICHR
ICHR
IDYA
IDYA
Q4 25
0.19×
Q3 25
0.18×
Q2 25
0.18×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.19×
Q2 24
0.19×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICHR
ICHR
IDYA
IDYA
Operating Cash FlowLast quarter
$9.2M
$142.2M
Free Cash FlowOCF − Capex
$5.9M
$142.2M
FCF MarginFCF / Revenue
2.6%
68.4%
Capex IntensityCapex / Revenue
1.5%
0.0%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$-6.3M
$13.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICHR
ICHR
IDYA
IDYA
Q4 25
$9.2M
Q3 25
$9.2M
$142.2M
Q2 25
$-7.5M
Q1 25
$19.0M
Q4 24
$-2.5M
Q3 24
$8.1M
$-49.2M
Q2 24
$17.5M
$-32.9M
Q1 24
$4.8M
$-43.8M
Free Cash Flow
ICHR
ICHR
IDYA
IDYA
Q4 25
$5.9M
Q3 25
$2.1M
$142.2M
Q2 25
$-14.8M
Q1 25
$496.0K
Q4 24
$-6.9M
Q3 24
$2.2M
$-49.7M
Q2 24
$14.6M
$-33.9M
Q1 24
$314.0K
$-45.1M
FCF Margin
ICHR
ICHR
IDYA
IDYA
Q4 25
2.6%
Q3 25
0.9%
68.4%
Q2 25
-6.2%
Q1 25
0.2%
Q4 24
-3.0%
Q3 24
1.0%
Q2 24
7.2%
Q1 24
0.2%
Capex Intensity
ICHR
ICHR
IDYA
IDYA
Q4 25
1.5%
Q3 25
3.0%
0.0%
Q2 25
3.0%
Q1 25
7.6%
Q4 24
1.9%
Q3 24
2.8%
Q2 24
1.4%
Q1 24
2.2%
Cash Conversion
ICHR
ICHR
IDYA
IDYA
Q4 25
Q3 25
1.19×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ICHR
ICHR

Other$101.6M45%
US$67.4M30%
Other Countries$29.7M13%
Europe$24.9M11%

IDYA
IDYA

Segment breakdown not available.

Related Comparisons